Pharmacologic and cytokine treatment of commonly encountered anemias.
Anemia has multiple etiologies: it may be caused by nutritional deficiencies or congenital abnormalities, or it may be associated with a number of conditions, such as chronic kidney disease, cancer, or human immunodeficiency virus (HIV) infection. Anemia is associated with an increase in morbidity and mortality in patients with endstage renal disease, cancer, or HIV infection. Each case of anemia is different, with different causes, clinical consequences, and treatment strategies. Identifying the most appropriate treatment requires an understanding of the etiology of the anemia and investigation of the nature of the causative medical condition. In some cases, such as anemia associated with chronic kidney disease, treatment is well defined and consists of administration of erythropoiesis-stimulating agents, accompanied by iron supplementation where appropriate. In other instances, such as megaloblastic anemia, which may be caused by vitamin or folate deficiency, vitamin supplementation alone may be a clinically appropriate treatment. This article gives an overview of the etiologies and current therapies of the most commonly encountered types of anemia, highlighting both the diverse nature of the condition, and the equally diverse pharmacologic and supportive treatment approaches.
Foote
MaryAnn
M
Amgen Inc., Thousand Oaks, CA 91230-1799, USA. mfoote@amgen.com
Colowick
Alan
A
Goodkin
David A
DA
D000740:Anemia / Q000188:drug therapy*; D001361:Avitaminosis / Q000628:therapy; D000068256:Darbepoetin alfa; D004912:Erythrocytes / Q000502:physiology*; D004920:Erythropoiesis / Q000502:physiology; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000276:immunology; D008954:Models, Biological
D004921:Erythropoietin; D000068256:Darbepoetin alfa